Author: Ken Dropiewski

HighLife Closes a €32 Million Round B Financing

PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced today it had closed a €32 million round of equity financing. Proceeds from the financing will be used to complete the development of the company’s transcatheter transseptal […]

THE SAGE GROUP Announces Publication of U.S. Acute Limb Ischemia (ALI) Incidence and Market Estimates

BEAUFORT, S.C.–(BUSINESS WIRE)–A new analysis published by THE SAGE GROUP concludes that ALI represents a substantial market opportunity for pharmaceutical and interventional therapies. “Although the number of patients currently treated for an acute occlusion in the lower limbs is relatively small, the total market is surprisingly large,” stated Mary L. […]

Edwards Lifesciences To Host Earnings Conference Call on January 31, 2019

IRVINE, Calif., Jan. 17, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2018 after the market closes on Thursday, January 31, 2019, and will host a conference call at 5:00 p.m. ET that […]

Correvio Provides Update On At The Market Offering

VANCOUVER, Jan. 17, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the completion of sales of all common shares qualified under its ATM Prospectus Supplement (defined below). The Company’s at-the-market sales issuance agreement, dated July 10, 2018, between the Company and […]

Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention

New Brunswick, NJ, January 17, 2019 — Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson […]

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval®. The results from the Perceval Aortic Heart Valve Study in North America, performed under a U.S. Food and Drug Administration (FDA) Investigational Device […]

Abbott To Acquire Cephea Valve Technologies, Inc.

ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an […]

Chocolate Touch® Drug-Coated Balloon IDE Study Expanded To Include Atherectomy

PLEASANTON, Calif., Jan. 16, 2019 /PRNewswire/ — QT Vascular Ltd., (the “Company” or “QT Vascular“, and together with its subsidiaries, the “Group“), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease. The Company is pleased to announce that […]